Sarcoma Trials - LARVOL Sigma

Sarcoma	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Sarcoma

NCT01661400: Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

Completed

Metronomic Cyclophosphamide, Cytoxan®, CPM, Thalidomide, Thalomid®

Washington University School of Medicine

Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Retinoblastoma

12/23

NCT02192359: Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Active, not recruiting

Carboxylesterase-expressing Allogeneic Neural Stem Cells, CE-secreting Allogeneic NSCs, hCE1m6-NSC, Irinotecan, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, U-101440E, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, Laboratory Biomarker Analysis, Pharmacological Study

City of Hope Medical Center, National Cancer Institute (NCI)

Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma, Recurrent WHO Grade III Glioma

02/22

12/24

NCT02298959: Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Active, not recruiting

Canada, US

Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Elastography, MRE, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Ziv-Aflibercept, Aflibercept, AVE0005, Eylea, Vascular Endothelial Growth Factor Trap, VEGF Trap, VEGF Trap R1R2, VEGF-Trap, Zaltrap

National Cancer Institute (NCI)

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8

12/24

NYMC195, NCT04308330 / 2008-003800-73: Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Recruiting

Vorinostat, Zolinza

New York Medical College

Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Neuroblastoma, Hepatoblastoma, Germ Cell Tumor

12/23

12/24

NRG-DT001, NCT03217266: Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

Active, not recruiting

Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

National Cancer Institute (NCI), NRG Oncology

Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma

08/23

02/25

ALLIANCE-ABTC-1604, NCT03107780: Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Recruiting

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

National Cancer Institute (NCI)

Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma

12/24

NCI-2019-01493, NCT03864419: Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Terminated

RoW

Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Cyclophosphamide, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, Emthexat, Emtexate, Methotrexate LPF, Methylaminopterin, Methotrexatum, Doxorubicin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, Adriamycine, Adriblastina, Doxolem, Doxorubicin.HCl, Prednisone, Deltacortene, Decorton, Decortisyl, DeCortin, Deltacortisone, Econosone, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Vepesid, Rituximab, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar JHL1101, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, RTXM83, Truxima

Fred Hutchinson Cancer Center

Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, Diffuse Large B-Cell Lymphoma

07/23

DIPG, NCT04341311: Phase I Study of Marizomib + Panobinostat for Children With

Terminated

Marizomib, salinosporamide A, salinosporin A, Panobinostat, Farydak

Dana-Farber Cancer Institute, Celgene, Secura Bio, Inc.

Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma

02/24

ChiCTR2200057036: A multicenter, randomized, double-blind, positive controlled phase II/III clinical study to evaluate the safety and efficacy of Laikubicin for injection in patients with advanced soft tissue sarcoma

Not yet recruiting

172

Legubicin ;Doxorubicin hydrochloride

Shanghai Sixth People's Hospital; Shanghai Avidity Bio-pharmaceutical Technology Co., Ltd., Shanghai Avidity Bio-pharmaceutical Technology Co., Ltd.

Soft tissue sarcoma

NCT05427513: Efficacy of Tranexamic Acid in Preventing Post Operative Blood Loss in Bone Sarcoma Patient

Recruiting

RoW

Tranexamic acid injection, normal saline

Shaukat Khanum Memorial Cancer Hospital & Research Centre

Blood Loss, Surgical

12/23

02/24

ChiCTR2200063055: Safety and efficacy of Tislelizumab in combination with doxorubicin in the first-line treatment of locally advanced or metastatic undifferentiated pleomorphic sarcoma: a prospective, single-arm, phase I study

Not yet recruiting

China

Tislelizumab, 200 mg, every three weeks

Beijing Jishuitan Hospital ; Beijing Jishuitan Hospital, Beigene Company

undifferentiated polymorphic sarcoma

SELISARC, NCT04595994: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma

Recruiting

Europe

Selinexor, Gemcitabine

Grupo Espanol de Investigacion en Sarcomas

Sarcoma,Soft Tissue

11/25

05/26

HFB-301001-01, NCT05229601: A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

Active, not recruiting

Europe, US

HFB301001

HiFiBiO Therapeutics

Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma

01/25

Cytalux, NCT06235125: Safety and Feasibility of Intraoperative Visualization With in Children

Not yet recruiting

Cytalux, Pafolacianine injection, OTL38 injection

Ann & Robert H Lurie Children's Hospital of Chicago, On Target Laboratories, LLC

Osteosarcoma, Pulmonary Metastasis, Fluorescence, Metastatic Sarcoma, Pediatrics

01/26

NCT04242238: Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Active, not recruiting

DCC-3014, Avelumab

Memorial Sloan Kettering Cancer Center, ENABLE MEDICINE

Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Dedifferentiated Liposarcoma

01/25

NCT03761095: A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Completed

Unesbulin, PTC596, Dacarbazine, DTIC

PTC Therapeutics

Leiomyosarcoma

02/24

NCI-2019-08556, NCT04420975: Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Active, not recruiting

Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, BO 112, BO-112, BO112, Nanoplexed Poly IC BO-112, Nanoplexed Polyinosinic:Polycytidylic Acid BO-112, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), Highlight Therapeutics

Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Soft Tissue Fibrosarcoma, Spindle Cell Sarcoma, Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Retroperitoneal Sarcoma AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Retroperitoneal Sarcoma AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Retroperitoneal Sarcoma AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Retroperitoneal Sarcoma AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Storiform-Pleomorphic Malignant Fibrous Histiocytoma, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells, Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant, Undifferentiated Spindle Cell Sarcoma

01/25

01/26

NCT04991870: Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma

Recruiting

Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Allogeneic CB-derived Ex vivo-expanded NK Cells, CB-derived Expanded Allogeneic NK Cells, UCB-derived Expanded Allogeneic NK Cells, Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection, Surgical Resection

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma

01/26

NCT01543763: Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

	ASCO 2016
	May 2016 - May 2016: ASCO 2016
	ASCO 2015
	May 2015 - May 2015: ASCO 2015
	ASCO 2014
	May 2014 - May 2014: ASCO 2014
	AACR-NCI-EORTC 2013
	Oct 2013 - Oct 2013: AACR-NCI-EORTC 2013
More

Active, not recruiting

PZP115891, PCI-24781, abexinostat, S 78454, GW786034, Votrient™, Pazopanib

Pamela Munster, Pharmacyclics LLC., Novartis, Xynomic Pharmaceuticals, Inc., GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease

Metastatic Solid Tumors

01/24

12/24

NCT03900793: Losartan + Sunitinib in Treatment of Osteosarcoma

Recruiting

Losartan, Sunitinib, Sunitinib Malate

University of Colorado, Denver

Osteosarcoma

08/26

02/27

NCT05698524: A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

Recruiting

PCI 24781, Abexinostat, Temozolomide, Temodar

University of Nebraska, Xynomic Pharmaceuticals, Inc.

Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma

02/25

06/27

NCT03462316: NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Active, not recruiting

RoW

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）

Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.

Bone Sarcoma, Soft Tissue Sarcoma

02/24

05/24

TQB2928-ALTN-Ib-01, NCT06438783: TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

Recruiting

RoW

1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Osteosarcoma, Other Solid Tumors

10/25

02/26

NCT01738139: Ipilimumab and Imatinib Mesylate in Advanced Cancer

Completed

Imatinib Mesylate, CGP 57148, CGP57148B, Gleevec, Glivec, STI 571, STI-571, STI571, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Gastrointestinal Stromal Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma, Unresectable Solid Neoplasm

12/22

12/23

NCT04176016: Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

Terminated

Japan

OTSA101-DTPA-111In, OTSA101-DTPA-90Y

OncoTherapy Science, Inc.

Relapsed or Refractory Synovial Sarcoma

01/24

NCT04389281: X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

Recruiting

X-PACT

Immunolight, LLC

Advanced Solid Tumor Cancer

09/24

08/25

SADDRIN-1, NCT05116254 / 2021-000042-17: Sarcomas and DDR-Inhibition; a Combined Modality Study

Recruiting

Europe

AZD1390 + radiotherapy, AZD1390 + durvlaumab + radiotherapy

The Netherlands Cancer Institute, Leiden University Medical Center, University Medical Center Nijmegen

Soft Tissue Sarcoma Adult

03/26

07/28

NCT05130255: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Recruiting

GD2-SADA:177Lu-DOTA Complex, two-step radioimmunotherapy

Y-mAbs Therapeutics

SCLC, Malignant Melanoma, Sarcoma

03/27

04/27

FLARES, NCT06252727: Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas

Not yet recruiting

Aminolevulinic Acid, 5-ALA, Gleolan

Steven W Thorpe, National Cancer Institute (NCI)

Soft Tissue Sarcoma, Soft Tissue Sarcoma Adult

02/26

05/26

NCT06242470: A Study of MGC026 in Participants With Advanced Solid Tumors

Recruiting

230

US, RoW

MGC026 Dose Escalation, MGC026 Dose for Expansion

MacroGenics

Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer

05/28

10/28

NCT06340204: Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Recruiting

RoW

Irinotecan Hydrochloride Liposome Injection, duo en yi

Peking University People's Hospital, Peking University Shougang Hospital, Shandong Cancer Hospital and Institute

Ewing Sarcoma

03/26

12/26

NCT04511871: A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Recruiting

RoW

CCT303-406

Shanghai PerHum Therapeutics Co., Ltd., Shanghai Zhongshan Hospital

Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer, Sarcoma

03/24

03/25

NCT05227326: AOH1996 for the Treatment of Refractory Solid Tumors

Active, not recruiting

PCNA Inhibitor AOH1996, AOH 1996, AOH-1996, AOH1996, Proliferating Cell Nuclear Antigen Inhibitor AOH1996

City of Hope Medical Center, National Cancer Institute (NCI)

Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas, Ovarian Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer

09/24

NCT01552434: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Active, not recruiting

155

Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Cetuximab, Cetuximab Biosimilar CMAB009, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Valproic Acid, Depakene, Stavzor, Valproate

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm

03/26

ChiCTR2100049429: Umbilical cord blood mononuclear cells alleviate adverse reactions of bone and soft tissue sarcoma and bone metastases: a randomized controlled, open-ended, multi-center phase I study

Recruiting

100

Receive neoadjuvant or adjuvant chemotherapy ;After receiving neoadjuvant or adjuvant chemotherapy, infusion of umbilical cord blood mononuclear cells is given within 24 hours

Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, self-funded

Bone and soft tissue sarcoma and bone metastasis cancer in new aided and chemotherapy-assisted chemotherapy

NCT05567601: Doxil/Caelyx BE Study

Not yet recruiting

DOXIL/CAELYX, doxorubicin hydrochloride liposome injection 2 mg/mL

Baxter Healthcare Corporation

Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer

04/24

NCT06008483: A Dose Finding Study to Treat Bone Tumor(s)

Recruiting

153-Sm-DOTMP (Samarium-153-DOTMP)

QSAM Therapeutics, Inc.

Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone, Metastatic Tumor to the Bone

04/24

11/24

NCT06228326: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Recruiting

KB707

Krystal Biotech, Inc.

Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer, Small Cell, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Sarcoma, Metastatic Osteosarcoma

02/27

NCT04397679: Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

Active, not recruiting

3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Intensity-Modulated Radiation Therapy (IMRT), IMRT, Intensity Modulated RT, INTENSITY-MODULATED RADIATION THERAPY, Intensity-Modulated Radiotherapy, Temozolomide, 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 362856, 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, 85622-93-1, CCRG-81045, imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, Imidazo[5,1-d], 1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temomedac, TMZ, Chloroquine, 54-05-7, Tumor Treating Fields Therapy (TTF), Alternating Electric Field Therapy, TTF, TTFields

Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)

Glioblastoma, Gliosarcoma

04/25

04/26

PBL-0405-01, NCT06273852: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Recruiting

PBA-0405, PB004.22.0405.aF

Pure Biologics S.A., Presage Biosciences

Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer

03/25

NCT01590069: Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Active, not recruiting

Aerosolized Aldesleukin, Aerosolized Recombinant IL-2, Laboratory Biomarker Analysis

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7

04/26

NCT04999761: AB122 Platform Study

Recruiting

715

Japan

AB122, TAS-116, TAS-120, TAS-115, TAS-102, Ramucirumab, Bevacizumab

Taiho Pharmaceutical Co., Ltd.

Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma

05/26

STARKAP, NCT05646082: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

Recruiting

Europe

Dostarlimab in Combination Antiretroviral Therapy

Imperial College London

Refractory HIV Associated Kaposi Sarcoma

05/24

09/25

NCT06299163: NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Recruiting

180

NM32-2668

Numab Therapeutics AG

Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma

12/27

NCT04299113: Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Recruiting

Vinorelbine, 3'',4''-Didehydro-4''-deoxy-C''-norvincaleukoblastine, 5''-Nor-Anhydrovinblastine, 71486-22-1, Dihydroxydeoxynorvinkaleukoblastine, nor-5''-Anhydrovinblastine, vinorelbine, VINORELBINE, Mocetinostat, 726169-73-9, Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-, MG-0103, MGCD0103, MGCD0103, N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide

Jonsson Comprehensive Cancer Center, Mirati Therapeutics Inc., Phase One Foundation

Rhabdomyosarcoma

05/25

05/26

NCT03120624: VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Active, not recruiting

Biopsy, Biopsy Type, BIOPSY_TYPE, Bx, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fluorine F 18 Tetrafluoroborate, 18F-Tetrafluoroborate, 18F-TFB, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Oncolytic VSV-hIFNbeta-NIS, Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Voyager-V1, VSV-expressing hIFNb and NIS, VSV-hIFNb-NIS, VSV-hIFNbeta-NIS, VV1, Ruxolitinib Phosphate, 1092939-17-7, INCB-18424 Phosphate, Jakafi, Jakavi, Technetium Tc-99m Sodium Pertechnetate, Pertscan-99m, Sodium Pertechnetate (Na99mtco4), Tc 99m Generator, Ultra-Technekow FM, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection

Mayo Clinic, National Cancer Institute (NCI)

Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinosarcoma, Stage IV Uterine Corpus Cancer AJCC v7

06/24

07/24

NCT03604783: Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors

Terminated

TP-1287

Sumitomo Pharma America, Inc.

Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma

01/24

NCT03635632: C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

Active, not recruiting

C7R-GD2.CART cells

Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, Cancer Prevention Research Institute of Texas

Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma, Relapsed Rhabdomyosarcoma, Uveal Melanoma, Phyllodes Breast Tumor

06/24

12/39

STRIvE-01, NCT03618381: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Recruiting

second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG

Seattle Children's Hospital

Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma

06/25

06/40

NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Recruiting

VAL-413, Orotecan®, Temozolomide, Temodar, Temodal, Temcad, TMZ

Valent Technologies, LLC

Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma

06/24

IMPACT, NCT06193759: Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy

Active, not recruiting

Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)

Children's National Research Institute

Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma, Embryonal Tumor of CNS

12/32

12/33

NCT02936102: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Active, not recruiting

154

Europe, Canada, Japan, US, RoW

FAZ053, PDR001

Novartis Pharmaceuticals

Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma

11/24

NCT06412458: IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Not yet recruiting

RoW

IM83 CAR-T Cells

Beijing Immunochina Medical Science & Technology Co., Ltd., Guangdong Provincial People's Hospital

Refractory Osteosarcoma, Recurrent Osteosarcoma

06/25

06/26

NCT03721068: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Recruiting

iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine

UNC Lineberger Comprehensive Cancer Center, United States Department of Defense, Bellicum Pharmaceuticals, University Cancer Research Fund at Lineberger Comprehensive Cancer Center

Neuroblastoma, Osteosarcoma

06/24

06/39

NCT06399419: CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Recruiting

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, CBM588 Capsules, CBM588, Clostridium butyricum MIYAIRI 588, C. butyricum MIYAIRI 588, C. butyricum strain MIYAIRI 588, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo

Osel, Inc., City of Hope Medical Center, Miyarisan Pharmaceuticals, Co., Ltd., National Cancer Institute (NCI)

Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8

10/26

NCT02020707: Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Active, not recruiting

Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Laboratory Biomarker Analysis, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Pharmacological Study

Mayo Clinic, National Cancer Institute (NCI)

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma, Cervical Squamous Cell Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Unresectable Melanoma, Uterine Corpus Carcinosarcoma

06/24

06/25

NCT02408861: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Recruiting

US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT

National Cancer Institute (NCI)

Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm

07/24

NCT03173976: Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Active, not recruiting

Zoledronic Acid, Zometa®

Mohammed Milhem, Rising Tide Foundation

Chondrosarcoma

07/24

NCT04047251: A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors

Recruiting

FF-10850 Topotecan Liposome Injection, FF-10850

Fujifilm Pharmaceuticals U.S.A., Inc.

Advanced Solid Tumors

03/25

07/26

NCT04457258: 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

Recruiting

Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Gallium Ga 68 FAPi-46, 68Ga-FAPi-46, Gallium-68-FAPi-46, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, 18F-FDG, 18F-fluorodeoxyglucose

Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)

Metastatic Sarcoma, Recurrent Sarcoma, Sarcoma

07/24

07/25

NCT03500991: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Active, not recruiting

HER2-specific chimeric antigen receptor (CAR) T cell

Seattle Children's Hospital

Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma

07/24

07/39

NCT06308419: A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Not yet recruiting

Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab-Sirolimus

M.D. Anderson Cancer Center, Aadi Bioscience

Leiomyosarcoma, Soft-tissue Sarcomas

02/29

02/31

NCT01189643: Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Active, not recruiting

irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator

Memorial Sloan Kettering Cancer Center, Genentech, Inc.

Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)

08/24

NCT03463408: Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

Active, not recruiting

nivolumab, ipilimumab

University of Rochester

Sarcoma

08/24

08/25

NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting

240

INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide

Inhibrx, Inc.

Solid Tumors, Malignant Pleural Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma, GIST, SDH-deficient Solid Tumors

12/25

07/26

NCT04530981: A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST

Active, not recruiting

Ripretinib, QINLOCK, Repaglinide

Deciphera Pharmaceuticals LLC

GIST - Gastrointestinal Stromal Tumor

11/23

03/25

NCT05488366: Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma

Recruiting

Pembrolizumab, MK-3475, Radiation therapy, RT

University of California, Irvine

Sarcoma, Soft Tissue

08/24

BrUOG 387, NCT05655598: TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Recruiting

Palbociclib Oral Product, TAS-116

Brown University

Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer

08/24

08/25

NCT04074564: MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Recruiting

RoW

MASCT-I, Camrelizumab,Apatinib

HRYZ Biotech Co.

Sarcoma

08/24

12/24

NCI-2018-01928, NCT03727789: CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

Terminated

FACT Complex-targeting Curaxin CBL0137, CBL0137

Roswell Park Cancer Institute, Incuron

Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma of the Extremity, Recurrent Sarcoma of the Extremity, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

01/24

NCT05128786: CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas

Recruiting

RoW

CCT301-38

Shanghai PerHum Therapeutics Co., Ltd., Shanghai Zhongshan Hospital

SAR

08/24

08/25

NCT05091866: Natural Progesterone for the Treatment of Recurrent Glioblastoma

Recruiting

Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Therapeutic Progesterone, Corlutina, Corluvite, Corpus luteum hormone, Cyclogest, Gestiron, Gestone, Lipo-Lutin, Luteohormone, Lutocyclin, Lutocylin M, Lutogyl, Lutromone, Progestasert, Progesterone, Progestin, Progestogel, Progestol, Progeston, Prolidon, Proluton, Syngesterone, Utrogestan

Emory University, National Cancer Institute (NCI)

Gliosarcoma, Recurrent Glioblastoma

08/25

08/26

NCT04634227: Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

Recruiting

Ascorbate

Mohammed Milhem, MBBS, University of Iowa

Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma

08/24

C134-HSV-1, NCT03657576: Trial of C134 in Patients With Recurrent GBM

Recruiting

C134

University of Alabama at Birmingham, Gateway for Cancer Research, National Cancer Institute (NCI)

Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain

09/24

09/25

NCT04092270: A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recruiting

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib

National Cancer Institute (NCI)

Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma

09/24

NCT04541082: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Recruiting

102

ONC206

Chimerix, National Institutes of Health (NIH)

Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma, Anaplastic Astrocytoma, Pilocytic Astrocytoma, Oligodendroglioma, Gliomatosis Cerebri, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Ependymoma, Anaplastic, Medulloblastoma, Teratoid Rhabdoid Tumor, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Anaplastic Meningioma, Atypical Meningioma, Choroid Plexus Neoplasms, Pineal Tumor, Diffuse Astrocytoma, Glial Tumor

09/24

02/25

NCT06117878: Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Recruiting

RoW

NK510

Base Therapeutics (Shanghai) Co., Ltd., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Osteosarcoma, Soft Tissue Sarcoma

09/24

NCT02496208: Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

	Data in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory metastatic GU tumors
	Feb 2021 - Feb 2021: Data in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory metastatic GU tumors
	Data from CaboNivo trial for genitourinary tumors at ESMO 2017 [screenshot]
	Sep 2017 - Sep 2017: Data from CaboNivo trial for genitourinary tumors at ESMO 2017 [screenshot]
	Urothelial carcinoma and other genitourinary tumors
	Feb 2017 - Feb 2017: Urothelial carcinoma and other genitourinary tumors
	From P1b trial of cabozantinib with nivolumab +/- ipilimumab in genitourinary tumors at ESMO
	Oct 2016 - Oct 2016: From P1b trial of cabozantinib with nivolumab +/- ipilimumab in genitourinary tumors at ESMO
More

Active, not recruiting

152

Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo

National Cancer Institute (NCI)

Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma

09/24

NCT05415098: Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Recruiting

APG-5918

Ascentage Pharma Group Inc.

Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma

09/24

09/25

NCT04477200: Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Recruiting

Mycophenolate Mofetil, MMF, Radiation Therapy, RT, Re-resection (as part of standard of care), Temozolomide, TMZ

University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)

Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV

10/24

10/27

NCT04282044: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Recruiting

CRX100 suspension for infusion, Fludarabine, Cyclophosphamide

BioEclipse Therapeutics

Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma

08/25

10/26

ALCI2, NCT01956084: Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma

Active, not recruiting

LMP1/2 CTLs (Group A), LMP1/2 CTLs (Group B)

Catherine Bollard

Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Severe Chronic Active EBV Infection Syndrome (SCAEBV), Leiomyosarcoma

10/24

11/25

ChiCTR2300068691: Pharmacokinetic study of anlotinib hydrochloride capsules in the treatment of relapsed or refractory pediatric sarcoma

Not yet recruiting

Anlotinib

The Children’s Hospital, Zhejiang University School of Medicine; The Children’s Hospital, Zhejiang University School of Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd

Sarcoma

NCT06414434: BTX-A51 in Patients With Liposarcoma

Not yet recruiting

BTX-A51, C32H41ClN6O6S2, (1r,4r)-N 1-(5-chloro-4-(5-(cyclopropylmethyl)-1-methyl-l H pyrazol-3-yl)pyrimidin-2-yl)cyclohexane-l ,4-diamine bis(4-methylbenzenesulfonate),

Michael Wagner, Edgewood Oncology Inc.

Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification

06/26

06/27

RESOLVE, NCT05154994: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma

Suspended

Belinostat, Beleodaq, PXD 101, PXD101, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736

University of Utah, National Cancer Institute (NCI)

Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma

11/24

11/26

NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting

VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)

VM Oncology, LLC

Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy

12/25

06/26

C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Recruiting

550

Europe, US

Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1

Agenus Inc.

Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer

DUET-3, NCT03752398: A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

Jan 2024 - Dec 2024: From DUET-3 trial for advanced solid tumors

Active, not recruiting

300

XmAb®23104, Yervoy® (ipilimumab)

Xencor, Inc., ICON plc

Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma

12/24

09/25

CHAPTER-GIST-101, NCT05245968: A Study of Pimitespib in Combination With Imatinib in Patients With GIST

Recruiting

Japan, RoW

Pimitespib, TAS-116, Imatinib, Sunitinib

Taiho Pharmaceutical Co., Ltd.

Gastrointestinal Stromal Tumors

12/25

HFB-200301-01, NCT05238883: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Recruiting

170

Europe, US

HFB200301, Tislelizumab, BGB-A317

HiFiBiO Therapeutics

Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma

12/26

NCT05538572: A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting

US, RoW

PRT3645

Prelude Therapeutics

Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer

12/24

NCT05858710: Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

Recruiting

Europe

DPPG2-TSL-DOX, Doxorubicin

Thermosome GmbH

Sarcoma, Soft Tissue

12/24

FHD-609-C-001, NCT04965753: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Terminated

Europe, US

FHD-609

Foghorn Therapeutics Inc.

Advanced Synovial Sarcoma

12/23

NCI-2018-00872, NCT03452930: Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

Active, not recruiting

Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Tinostamustine, 1H-Benzimidazole-2-heptanamide, 5-(Bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-, EDO-S 101, EDO-S-101, EDO-S101

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma

12/24

NCT02812420: Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Active, not recruiting

Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Therapeutic Conventional Surgery, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma

12/24

SJ-0003, NCT03594422: A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Recruiting

100

RoW

HQP1351

Ascentage Pharma Group Inc., HealthQuest Pharma Inc.

Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult

12/24

12/26

RG1121403, NCT04797767: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Suspended

Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Mitoxantrone, Dihydroxyanthracenedione, Mitozantrone, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto

University of Washington, AbbVie

Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myeloid Neoplasm, Relapsed Acute Biphenotypic Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Mixed Phenotype Acute Leukemia, Relapsed Myeloid Neoplasm, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myeloid Neoplasm, Recurrent Myeloid Sarcoma

12/24

ChiCTR2300075156: Phase I clinical study on tolerability, safety, and efficacy of Dalpiciclib combined with Apatinib in the treatment of patients with advanced or metastatic sarcoma

Not yet recruiting

Dalpiciclib 100mg once daily oral d1-21+Apatinib 250mg once daily oral d1-28, every 28 days as one cycle; ;Dalpiciclib 100mg once daily oral d1-21+Apatinib 500mg once daily oral d1-28, every 28 days as one cycle; ;Dalpiciclib 150mg once daily oral d1-21+Apatinib 500mg once daily oral d1-28, every 28 days as one cycle;

Peking University Third Hospital; Peking University Third Hospital, Self-fding

Sarcoma

NCT06474676: T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Not yet recruiting

Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy, AttIL2-TIL

M.D. Anderson Cancer Center

Metastatic Soft-tissue Sarcoma

12/30

12/32

NCT04199026: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Not yet recruiting

Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Drug Delivery Microdevice, Microdevice, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Pazopanib, GW786034, Polyethylene Glycol, Glycol, polyethylene, PEG, Poly(oxyethylene), Polyethylene Glycol 400, Polyethylene Glycol 8000, POLYETHYLENE GLYCOL, UNSPECIFIED, Polyethylene Oxide, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine, LEUROCRISTINE, VCR, Vincrystine

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma

12/25



	Diseases Companies Products Productz Mechanisms of Action Sites